Skip to main content

Table 1 Studies Used in Analysis

From: Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder

Study Population Duration (weeks) Dose (mg/day) Inclusion Criteria Fasting Labs
HGLB17 Schizophrenia 28 10-20 (i) PANSS Total ≥75
(ii) PANSS Positive ≥4
(iii) CGI-S ≥4
Yes
HGJU18 Schizophrenia, Schizoaffective with Comorbid Depression 24 10-20 (i) MADRS Total ≥16
(ii) MADRS item #2 ≥4
Yes
HGJB19 Schizophrenia, Schizoaffective with negative Symptoms 24 10-20 (i) GAF ≤60
(ii) PANSS Negative ≥4 on at least 3 items or ≥5 on at least 2 items
No
HGHJ20 Schizophrenia 28 10-20 (i) BPRS ≥42
(ii) PANSS Positive ≥4
(iii) CGI-S ≥4
Yes
HGBG21 Schizophrenia, Schizophreniform, Schizoaffective 28 10-20 (i) BPRS ≥42 No
HGGN22 Schizophrenia, Schizoaffective 52 5-20 (i) Illness duration ≥2 yrs
(ii) PANSS Positive≥4 on 2 items
(iii) BPRS ≥18
No
  1. Abbreviations: PANSS = Positive and negative syndrome scale; CGI-S = Clinical global impression of severity; MADRS = Montgomery Asberg depression rating scale; GAF = Global assessment of functioning; BPRS = Brief psychiatric rating scale